Probenecid Sensitizes Neuroblastoma Cancer Stem Cells to Cisplatin

References

• Pabla N, Dong Z. Curtailing side effects in chemotherapy: a tale of PKCdelta in cisplatin treatment. Oncotarget 2012; 3(1):107–111.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 2005;148:107–121.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2(1):48–58.
   PubMed Web of Science ®Google Scholar
• Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008;1(2):93–105.
   PubMedGoogle Scholar
• Elliott A, Adams J, Al-Hajj M. The ABCs of cancer stem cell drug resistance. IDrugs 2010;13(9):632–635.
   PubMed Web of Science ®Google Scholar
• Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, et al. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One 2012;7(4):e35040.
   PubMed Web of Science ®Google Scholar
• Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004;101(3):781–786.
   PubMed Web of Science ®Google Scholar
• Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12(12):2607–2613.
   PubMed Web of Science ®Google Scholar
• Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991;9(6):1050–1058.
   PubMed Web of Science ®Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9(3):247–256.
   PubMed Web of Science ®Google Scholar
• Campos-Arroyo D, Martinez-Lazcano JC, Melendez-Zajgla J. Probenecid is a chemosensitizer in cancer cell lines. Cancer Chemother Pharmacol 2012;69(2):495–504.
   PubMed Web of Science ®Google Scholar
• Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006;312(19):3701–3710.
   PubMed Web of Science ®Google Scholar
• Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 2001;7(9):1028–1034.
   PubMed Web of Science ®Google Scholar
• Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research 2007;67(10):4827–4833.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355(12):1253–1261.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105–111.
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106(33):13820–13825.
   PubMed Web of Science ®Google Scholar
• Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012;14(1):202.
   PubMed Web of Science ®Google Scholar
• Chakrabarti L, Abou-Antoun T, Vukmanovic S, Sandler AD. Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front Oncol 2012; 2:82.
   PubMedGoogle Scholar
• Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, et al. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 2010;5(11):e13943.
   PubMed Web of Science ®Google Scholar
• Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011;3(11):623–636.
   PubMed Web of Science ®Google Scholar
• Beyer KH, Wiebelhaus VD, Tillson EK, Russo HF, Wilhoyte KM. 'Benemid', p-(di-npropylsulfamyl)-benzoic acid: inhibition of glycine conjugative reactions. Proc Soc Exp Biol Med 1950;74(4):772–775.
   PubMed Web of Science ®Google Scholar
• Boger WP, Strickland SC. Probenecid (benemid); its uses and side-effects in 2,502 patients. AMA Arch Intern Med 1955;95(1):83–92.
   PubMedGoogle Scholar
• Berner W, Kinne R. Transport of p-aminohippuric acid by plasma membrane vesicles isolated from rat kidney cortex. Pflugers Arch 1976;361(3):269–277.
   PubMed Web of Science ®Google Scholar
• Yesair DW, Remington L, Callahan M, Kensler CJ. Comparative effects of salicylic acid, phenylbutazone, probenecid and other anions on the metabolism, distribution and excretion of indomethacin by rats. Biochem Pharmacol 1970;19(5):1591–1600.
   PubMed Web of Science ®Google Scholar
• Diamond HS, Sharon E. Evidence for a post-secretory reabsorptive site for uric acid in man. Adv Exp Med Biol 1974;41:745–749.
   PubMedGoogle Scholar
• Kenwright S, Levi AJ. Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications. Lancet 1973;2(7843):1401–1405.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei Y, Sawchuk RJ. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J Pharm Sci 1997;86(12):1484–1490.
   PubMed Web of Science ®Google Scholar
• Stamp LK, O'Donnell JL, Chapman PT. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J 2007;37(4):258–266.
   PubMed Web of Science ®Google Scholar
• Moller JV. The tubular site of urate transport in the rabbit kidney, and the effect of probenecid on urate secretion. Acta Pharmacol Toxicol (Copenh) 1965;23(4):329–336.
   PubMedGoogle Scholar
• Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 1998;438(3):321–324.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Moccio DM, Young CW. Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux. Cancer Res 1981;41(3):966–970.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW. Inhibition of cisdiamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 1984;44(8):3632–3635.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Wendel HG, Bornmann WG, Tong WP, Miller VA, Scher HI, et al. Coadministration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 2000;6(9):3705–3712.
   PubMed Web of Science ®Google Scholar
• Khokhar NZ, She Y, Rusch VW, Sirotnak FM. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin Cancer Res 2001;7(10):3199–3205.
   PubMed Web of Science ®Google Scholar
• Elinos-Baez CM, Maldonado V, Melendez-Zajgla J. Caspases: apoptosis inducing molecules. Gac Med Mex 2003;139(5):493–499.
   PubMedGoogle Scholar
• Maldonado V, Melendez-Zajgla J, Ortega A. Modulation of NF-kappa B, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Mutat Res 1997;381(1):67–75.
   PubMed Web of Science ®Google Scholar
• Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, et al. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 2013;73(13):4134–4146.
   PubMed Web of Science ®Google Scholar
• Bader P, Schilling F, Schlaud M, Girgert R, Handgretinger R, Klingebiel T, et al. Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep 1999;6(5):1143–1146.
   PubMed Web of Science ®Google Scholar
• Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994;54(19):5036–5040.
   PubMed Web of Science ®Google Scholar
• Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 1997;33(12):2031–2036.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Shirasawa H, Hishiki T, Enomoto H, Kouchi K, Ohtsuka Y, et al. Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior. Jpn J Cancer Res 1998;89(12):1276–1283.
   PubMedGoogle Scholar
• Pajic M, Norris MD, Cohn SL, Haber M. The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Lett 2005;228(1-2):241–246.
   PubMed Web of Science ®Google Scholar